87.20
price down icon0.50%   -0.44
after-market After Hours: 87.20
loading
Soleno Therapeutics Inc stock is traded at $87.20, with a volume of 1.19M. It is down -0.50% in the last 24 hours and up +9.85% over the past month. Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
See More
Previous Close:
$87.64
Open:
$88.25
24h Volume:
1.19M
Relative Volume:
1.13
Market Cap:
$4.39B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-29.10
EPS:
-2.9966
Net Cash Flow:
$-24.94M
1W Performance:
+6.91%
1M Performance:
+9.85%
6M Performance:
+86.01%
1Y Performance:
+87.97%
1-Day Range:
Value
$86.24
$88.82
1-Week Range:
Value
$80.91
$88.82
52-Week Range:
Value
$41.50
$90.32

Soleno Therapeutics Inc Stock (SLNO) Company Profile

Name
Name
Soleno Therapeutics Inc
Name
Phone
650-213-8444
Name
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Name
Employee
92
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
SLNO's Discussions on Twitter

Compare SLNO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SLNO
Soleno Therapeutics Inc
87.20 4.30B 0 -38.99M -24.94M -2.9966
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.81 120.40B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
542.52 61.30B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.53 41.06B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
564.59 34.29B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.55 27.09B 3.81B -644.79M -669.77M -6.24

Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-23-25 Initiated TD Cowen Buy
Mar-05-25 Resumed Stifel Buy
Dec-02-24 Reiterated Robert W. Baird Outperform
Dec-02-24 Reiterated Stifel Buy
Sep-03-24 Initiated H.C. Wainwright Buy
May-10-24 Initiated Robert W. Baird Outperform
Feb-05-24 Initiated Piper Sandler Overweight
Jan-23-24 Initiated Stifel Buy
Nov-21-23 Resumed Guggenheim Buy
Sep-29-20 Initiated Guggenheim Buy
Jan-10-20 Initiated Craig Hallum Buy
Dec-23-19 Initiated Oppenheimer Outperform
Feb-13-18 Reiterated Maxim Group Buy
View All

Soleno Therapeutics Inc Stock (SLNO) Latest News

pulisher
Jul 19, 2025

What analysts say about Soleno Therapeutics Inc. stockPhenomenal investment performance - Autocar Professional

Jul 19, 2025
pulisher
Jul 19, 2025

Soleno gains as Betaville cites buyout interest (update) - MSN

Jul 19, 2025
pulisher
Jul 19, 2025

Soleno Therapeutics Inc. Stock Analysis and ForecastConsistent triple-digit returns - Jammu Links News

Jul 19, 2025
pulisher
Jul 19, 2025

Is Soleno Therapeutics Inc. a good long term investmentHigh-profit capital plays - Jammu Links News

Jul 19, 2025
pulisher
Jul 18, 2025

(SLNO) Trading Report - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 16, 2025

Soleno Therapeutics: A Strategic Capital Raise Balances M&A Optionality with Long-Term Growth Potential - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Soleno Therapeutics: Fairly Valued Despite M&A Expectations - Seeking Alpha

Jul 16, 2025
pulisher
Jul 15, 2025

Soleno Therapeutics (SLNO) Receives a Buy from Oppenheimer - The Globe and Mail

Jul 15, 2025
pulisher
Jul 14, 2025

Mintz Advises on Soleno Therapeutics’ $200 Million Public Offering - Mintz

Jul 14, 2025
pulisher
Jul 13, 2025

Soleno Therapeutics Shares Dip Following $200 Million Stock Offering Pricing - MSN

Jul 13, 2025
pulisher
Jul 12, 2025

Soleno Therapeutics stock dips on proposed $200M offering - MSN

Jul 12, 2025
pulisher
Jul 12, 2025

Baird Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Raises Target Price to $121 - 富途牛牛

Jul 12, 2025
pulisher
Jul 11, 2025

Stifel reiterates Buy rating on Soleno Therapeutics stock amid strong Vykat launch - Investing.com Nigeria

Jul 11, 2025
pulisher
Jul 11, 2025

Stifel reiterates Buy rating on Soleno Therapeutics stock amid strong Vykat launch By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 11, 2025

Soleno Therapeutics Announces Public Stock Offering - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch - insights.citeline.com

Jul 11, 2025
pulisher
Jul 11, 2025

Soleno Therapeutics stock soars as Stifel reiterates Buy on strong Vykat sales - Investing.com Australia

Jul 11, 2025
pulisher
Jul 11, 2025

Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - GlobeNewswire

Jul 11, 2025
pulisher
Jul 10, 2025

Baird raises Soleno Therapeutics stock price target to $121 on strong Vykat XR sales - Investing.com Nigeria

Jul 10, 2025
pulisher
Jul 10, 2025

Firm Advises Soleno Therapeutics on $200 Million Public Offering - Wilson Sonsini

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno reports preliminary Q2 revenue of $31-33 million for VYKAT XR - Investing.com Nigeria

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock - GlobeNewswire

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno sales of new Prader-Willi drug rise faster than expected - BioPharma Dive

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno Therapeutics Prices $200 Mln Public Offering To Support VYKAT XR Launch - Nasdaq

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno Therapeutics stock falls after pricing $200 million offering By Investing.com - Investing.com Canada

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno Therapeutics stock falls after pricing $200 million offering - Investing.com

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno Therapeutics prices public offering at $85 per share - Investing.com

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno Therapeutics prices public offering at $85 per share By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno Therapeutics prices $200M public offering - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno Therapeutics Secures $200M Public Offering to Commercialize Breakthrough Prader-Willi Treatment - Stock Titan

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno Therapeutics stock soars as Stifel reiterates Buy on strong Vykat sales By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno Therapeutics: Q2 2025 Results Signal Breakout Potential in Rare Disease Market - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno Therapeutics announces preliminary financial and operational results for Q2 - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno Therapeutics' $200M Secondary Offering: Catalyst for Growth or Dilution Danger Zone? - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno Therapeutics Reports Q2 Preliminary Net Revenue - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno Therapeutics Proposes $200 Million Public Offering - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno Therapeutics Reports Preliminary Financial Results for Q2 2025, Anticipating $31-$33 Million in Revenue from VYKAT™ XR - Nasdaq

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno Therapeutics Announces Preliminary Financial and - GlobeNewswire

Jul 10, 2025
pulisher
Jul 10, 2025

Soleno's New Drug VYKAT XR Hits $33M Revenue in First Quarter Launch with Nearly 300 Prescribers - Stock Titan

Jul 10, 2025
pulisher
Jul 09, 2025

Soleno Therapeutics (SLNO) Soars 5.93% on Regulatory Milestone - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI) and Soleno Therapeutics (SLNO) - The Globe and Mail

Jul 09, 2025
pulisher
Jul 08, 2025

Soleno Therapeutics stock price target raised to $115 by Stifel on strong Vykat demand - Investing.com South Africa

Jul 08, 2025
pulisher
Jul 08, 2025

Soleno Therapeutics stock poised for success as Piper Sandler sees $2B+ potential - Investing.com Nigeria

Jul 08, 2025
pulisher
Jul 08, 2025

(SLNO) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Jul 08, 2025
pulisher
Jul 07, 2025

Soleno Therapeutics stock price target raised to $115 from $108 at Stifel - Investing.com Nigeria

Jul 07, 2025
pulisher
Jul 07, 2025

Soleno Therapeutics stock price target raised to $115 from $108 at Stifel By Investing.com - Investing.com South Africa

Jul 07, 2025
pulisher
Jul 07, 2025

Soleno Therapeutics stock poised for success as Piper Sandler sees $2B+ potential By Investing.com - Investing.com South Africa

Jul 07, 2025

Soleno Therapeutics Inc Stock (SLNO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.88
price down icon 0.59%
$35.59
price up icon 0.34%
$102.56
price down icon 1.55%
$26.20
price down icon 5.18%
$110.02
price down icon 0.92%
biotechnology ONC
$294.55
price up icon 1.45%
Cap:     |  Volume (24h):